Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in ViennaReport as inadecuate




Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna - Download this document for free, or read online. Document in PDF available to download.

Wiener klinische Wochenschrift

pp 1–10

First Online: 27 January 2017Received: 18 August 2016Accepted: 19 December 2016DOI: 10.1007-s00508-016-1162-y

Cite this article as: Steiner, S., Bucsics, T., Schwabl, P. et al. Wien Klin Wochenschr 2017. doi:10.1007-s00508-016-1162-y Summary

AimWe aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir-ledipasvir SOF-LDV and ritonavir boosted paritaprevir-ombitasvir with or without dasabuvir 2D-3D regimens in a real-life cohort of human immunodeficiency virus-hepatitis C virus HIV-HCV coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy ART due to drug-drug interaction DDI, and treatment-associated changes in liver stiffness.

MethodsIn this study 36 patients n = 21 SOF-LDV and n = 15 2D-3D were retrospectively analyzed. Depending on the genotype the following treatment regimens were used: HCV genotype GT-1: either SOF-LDV or 3D, no patient with HCV-GT2 was included, HCV-GT3: SOF-LDV, HCV-GT4: 2D.

ResultsApproximately one third 35.3% of patients were treatment-experienced and 13.9% had cirrhosis. Antiretroviral therapy had to be changed in 38.1% of SOF-LDV and 60% of 2D-3D patients prior to anti-HCV treatment due to expected DDIs. We observed sustained virologic response SVR rates of 100% in patients treated with SOF-LDV 19-19 and 2D-3D 14-14. One 2D-3D patient was lost to follow-up, while two SOF-LDV patients died during therapy from non-treatment-related causes. They were excluded from the analysis. Between baseline and follow-up liver stiffness decreased from 11.4 to 8.3 kPa p = 0.008 and from 8.1 to 5.7 kPa p = 0.001 in SOF-LDV and 2D-3D patients, respectively.

ConclusionsWe confirmed the excellent HCV eradication rates >95% in a real-life cohort of HIV-HCV coinfected patients treated with SOF-LDV and 2D-3D. We observed no HCV relapse or breakthrough. More patients treated with 2D-3D required a change in ART than patients treated with SOF-LDV. Additionally, HCV eradication led to a rapid decline in liver stiffness.

KeywordsHIV Hepatitis C virus Sofosbuvir Ledipasvir 3D 



Author: Sebastian Steiner - Theresa Bucsics - Philipp Schwabl - Mattias Mandorfer - Bernhard Scheiner - Maximilian Christopher Aich

Source: https://link.springer.com/







Related documents